Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2013

Open Access 01-12-2013 | Research

Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes

Authors: Roberto Gomez-Casal, Chitralekha Bhattacharya, Nandita Ganesh, Lisa Bailey, Per Basse, Michael Gibson, Michael Epperly, Vera Levina

Published in: Molecular Cancer | Issue 1/2013

Login to get access

Abstract

Ionizing radiation (IR) is used for patients diagnosed with unresectable non small cell lung cancer (NSCLC), however radiotherapy remains largely palliative due to radioresistance. Cancer stem cells (CSCs), as well as epithelial-mesenchymal transition (EMT), may contribute to drug and radiation resistance mechanisms in solid tumors. Here we investigated the molecular phenotype of A549 and H460 NSCLC cells that survived treatment with IR (5Gy) and are growing as floating tumor spheres and cells that are maintained in a monolayer after irradiation.
Non-irradiated and irradiated cells were collected after one week, seeded onto ultra low attachment plates and propagated as tumor spheres. Bulk NSCLC cells which survived radiation and grew in spheres express cancer stem cell surface and embryonic stem cell markers and are able to self-renew, and generate differentiated progeny. These cells also have a mesenchymal phenotype. Particularly, the radiation survived sphere cells express significantly higher levels of CSC markers (CD24 and CD44), nuclear β-catenin and EMT markers (Snail1, Vimentin, and N-cadherin) than non-irradiated lung tumor sphere cells. Upregulated levels of Oct-4, Sox2 and beta-catenin were detected in H460 cells maintained in a monolayer after irradiation, but not in radiation survived adherent A459 cells.
PDGFR-beta was upregulated in radiation survived sphere cells and in radiation survived adherent cells in both A549 and H460 cell lines. Combining IR treatment with axitinib or dasatinib, inhibitors with anti-PDFGR activity, potentiates the efficacy of NSCLC radiotherapy in vitro.
Our findings suggest that radiation survived cells have a complex phenotype combining the properties of CSCs and EMT. CD44, SNAIL and PDGFR-beta are dramatically upregulated in radiation survived cells and might be considered as markers of radiotherapy response in NSCLC.
Appendix
Available only for authorised users
Literature
1.
2.
Parsons A, Daley A, Begh R, Aveyard P: Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ. 2010, 340: b5569-PubMedCentralCrossRefPubMed
3.
Greco FA, Stroup SL, Gray JR, Hainsworth JD: Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1996, 14 (5): 1642-1648.PubMed
4.
Danesi R, Pasqualetti G, Giovannetti E, Crea F, Altavilla G, Del Tacca M, Rosell R: Pharmacogenomics in non-small-cell lung cancer chemotherapy. Advanced drug delivery reviews. 2009, 61 (5): 408-417.CrossRefPubMed
5.
Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nat Geosci. 2001, 414 (6859): 105-111.
6.
Reya T, Clevers H: Wnt signalling in stem cells and cancer. Nat Geosci. 2005, 434 (7035): 843-850.
7.
8.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003, 100 (7): 3983-3988.PubMedCentralCrossRefPubMed
9.
Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS: In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003, 17 (10): 1253-1270.PubMedCentralCrossRefPubMed
10.
Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007, 1 (3): 313-323.CrossRefPubMed
11.
Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA: Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia. 2002, 39 (3): 193-206.CrossRefPubMed
12.
Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008, 15 (3): 504-514.CrossRefPubMed
13.
Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE: Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE. 2008, 3 (8): e3077-PubMedCentralCrossRefPubMed
14.
Gorelik E, Lokshin A, Levina V: Lung cancer stem cells as a target for therapy. Anticancer Agents Med Chem. 2010, 10 (2): 164-171.CrossRefPubMed
15.
16.
Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 2005, 5 (4): 275-284.CrossRefPubMed
17.
Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S: Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A. 2009, 106 (38): 16281-16286.PubMedCentralCrossRefPubMed
18.
Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA: Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 2009, 7 (3): 330-338.PubMedCentralCrossRefPubMed
19.
Levina V, Marrangoni A, Wang T, Parikh S, Su Y, Herberman R, Lokshin A, Gorelik E: Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res. 2010, 70 (1): 338-346.PubMedCentralCrossRefPubMed
20.
Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S, Soh BS, Sun LL, Tai BC, Nga ME: Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell. 2012, 148 (1–2): 259-272.CrossRefPubMed
21.
Ho MM, Ng AV, Lam S, Hung JY: Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007, 67 (10): 4827-4833.CrossRefPubMed
22.
Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S, Chellappan SP: EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Molecular cancer. 2012, 11: 73-PubMedCentralCrossRefPubMed
23.
Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY: Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE. 2008, 3 (7): e2637-PubMedCentralCrossRefPubMed
24.
Giangreco A, Lu L, Vickers C, Teixeira VH, Groot KR, Butler CR, Ilieva EV, George PJ, Nicholson AG, Sage EK: beta-catenin determines upper airway progenitor cell fate and preinvasive squamous lung cancer progression by modulating epithelial-mesenchymal transition. J Pathol. 2012, 226 (4): 575-587.PubMedCentralCrossRefPubMed
25.
Teng Y, Wang X, Wang Y, Ma D: Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Commun. 2010, 392 (3): 373-379.CrossRefPubMed
26.
Shien K, Toyooka S, Ichimura K, Soh J, Furukawa M, Maki Y, Muraoka T, Tanaka N, Ueno T, Asano H: Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer. 2012, 77 (1): 162-167.CrossRefPubMed
27.
28.
Kong D, Li Y, Wang Z, Sarkar FH: Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins?. Cancers (Basel). 2011, 3 (1): 716-729.CrossRef
29.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008, 133 (4): 704-715.PubMedCentralCrossRefPubMed
30.
Scheel C, Weinberg RA: Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol. 2012, 22 (5-6): 396-403.CrossRefPubMed
31.
Wijnhoven BP, Dinjens WN, Pignatelli M: E-cadherin-catenin cell-cell adhesion complex and human cancer. The British journal of surgery. 2000, 87 (8): 992-1005.CrossRefPubMed
32.
Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, Bell G, Guo W, Rubin J, Richardson AL: Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell. 2011, 145 (6): 926-940.PubMedCentralCrossRefPubMed
33.
Polyak K, Weinberg RA: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009, 9 (4): 265-273.CrossRefPubMed
34.
Craene BD, Berx G: Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2012, 13 (2): 97-110.CrossRef
35.
Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN: The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 2009, 8 (20): 3274-3284.PubMedCentralCrossRefPubMed
36.
Salnikov AV, Liu L, Platen M, Gladkich J, Salnikova O, Ryschich E, Mattern J, Moldenhauer G, Werner J, Schemmer P: Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential. PLoS One. 2012, 7 (9): e46391-PubMedCentralCrossRefPubMed
37.
Andarawewa KL, Erickson AC, Chou WS, Costes SV, Gascard P, Mott JD, Bissell MJ, Barcellos-Hoff MH: Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition. Cancer Res. 2007, 67 (18): 8662-8670.CrossRefPubMed
38.
Jung JW, Hwang SY, Hwang JS, Oh ES, Park S, Han IO: Ionising radiation induces changes associated with epithelial-mesenchymal transdifferentiation and increased cell motility of A549 lung epithelial cells. Eur J Cancer. 2007, 43 (7): 1214-1224.CrossRefPubMed
39.
Zhou P, Du LF, Lv GQ, Yu XM, Gu YL, Li JP, Zhang C: Functional polymorphisms in CD166/ALCAM gene associated with increased risk for breast cancer in a Chinese population. Breast Cancer Res Treat. 2011, 128 (2): 527-534.CrossRefPubMed
40.
Kawamoto A, Yokoe T, Tanaka K, Saigusa S, Toiyama Y, Yasuda H, Inoue Y, Miki C, Kusunoki M: Radiation induces epithelial-mesenchymal transition in colorectal cancer cells. Oncol Rep. 2012, 27 (1): 51-57.PubMed
41.
Kim H, Yoo SB, Sun P, Jin Y, Jheon S, Lee CT, Chung JH: Alteration of the E-cadherin/beta-catenin complex is an independent poor prognostic factor in lung adenocarcinoma. Korean journal of pathology. 2013, 47 (1): 44-51.PubMedCentralCrossRefPubMed
42.
Hall EJ: Radiation dose-rate: a factor of importance in radiobiology and radiotherapy. The British journal of radiology. 1972, 45 (530): 81-97.CrossRefPubMed
43.
Denker SP, Barber DL: Cell migration requires both ion translocation and cytoskeletal anchoring by the Na-H exchanger NHE1. The Journal of cell biology. 2002, 159 (6): 1087-1096.PubMedCentralCrossRefPubMed
44.
Levina V, Marrangoni AM, Demarco R, Gorelik E, Lokshin AE: Multiple effects of TRAIL in human carcinoma cells: Induction of apoptosis, senescence, proliferation, and cytokine production. Exp Cell Res. 2008, 314 (7): 1605-1616.PubMedCentralCrossRefPubMed
45.
Jung MJ, Rho JK, Kim YM, Jung JE, Jin YB, Ko YG, Lee JS, Lee SJ, Lee JC, Park MJ: Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene. 2013, 32 (2): 209-221.CrossRefPubMed
46.
Ball SG, Shuttleworth A, Kielty CM: Inhibition of platelet-derived growth factor receptor signaling regulates Oct4 and Nanog expression, cell shape, and mesenchymal stem cell potency. Stem Cells. 2012, 30 (3): 548-560.PubMedCentralCrossRefPubMed
47.
Gupta PB, Chaffer CL, Weinberg RA: Cancer stem cells: mirage or reality?. Nat Med. 2009, 15 (9): 1010-1012.CrossRefPubMed
48.
Ofori-Acquah SF, King JA: Activated leukocyte cell adhesion molecule: a new paradox in cancer. Translational research: the journal of laboratory and clinical medicine. 2008, 151 (3): 122-128.CrossRef
49.
Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L, Zlobec I: Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer. 2010, 103 (3): 382-390.PubMedCentralCrossRefPubMed
50.
Haynes BF, Liao HX, Patton KL: The transmembrane hyaluronate receptor (CD44): multiple functions, multiple forms. Cancer Cells. 1991, 3 (9): 347-350.PubMed
51.
Zoller M: CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. Nat Rev Cancer. 2011, 11 (4): 254-267.CrossRefPubMed
52.
Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, Ghatak S: Hyaluronan-CD44 interactions as potential targets for cancer therapy. The FEBS journal. 2011, 278 (9): 1429-1443.PubMedCentralCrossRefPubMed
53.
Katoh M: WNT signaling in stem cell biology and regenerative medicine. Curr Drug Targets. 2008, 9 (7): 565-570.CrossRefPubMed
54.
de Jong MC, Pramana J, van der Wal JE, Lacko M, Peutz-Kootstra CJ, de Jong JM, Takes RP, Kaanders JH, van der Laan BF, Wachters J: CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res. 2010, 16 (21): 5329-5338.CrossRefPubMed
55.
Calloni R, Cordero EA, Henriques JA, Bonatto D: Reviewing and updating the major molecular markers for stem cells. Stem Cells Dev. 2013, 22 (9): 1455-1476.PubMedCentralCrossRefPubMed
56.
57.
Tellez CS, Juri DE, Do K, Bernauer AM, Thomas CL, Damiani LA, Tessema M, Leng S, Belinsky SA: EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res. 2011, 71 (8): 3087-3097.PubMedCentralCrossRefPubMed
58.
Ouyang G, Wang Z, Fang X, Liu J, Yang CJ: Molecular signaling of the epithelial to mesenchymal transition in generating and maintaining cancer stem cells. Cell Mol Life Sci. 2010, 67 (15): 2605-2618.CrossRefPubMed
59.
60.
Lee HJ, Choe G, Jheon S, Sung SW, Lee CT, Chung JH: CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification. J Thorac Oncol. 2010, 5 (5): 649-657.PubMed
61.
Kang KS, Choi YP, Gao MQ, Kang S, Kim BG, Lee JH, Kwon MJ, Shin YK, Cho NH: CD24(+) ovary cancer cells exhibit an invasive mesenchymal phenotype. Biochem Biophys Res Commun. 2013, 432 (2): 333-338.CrossRefPubMed
62.
Yang J, Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Developmental cell. 2008, 14 (6): 818-829.CrossRefPubMed
63.
Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA: Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008, 68 (10): 3645-3654.CrossRefPubMed
64.
Hung JJ, Yang MH, Hsu HS, Hsu WH, Liu JS, Wu KJ: Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax. 2009, 64 (12): 1082-1089.CrossRefPubMed
65.
Martin A, Cano A: Tumorigenesis: twist1 links EMT to self-renewal. Nature cell biology. 2010, 12 (10): 924-925.CrossRefPubMed
66.
Barnes RM, Firulli AB: A twist of insight - the role of twist-family bHLH factors in development. The International journal of developmental biology. 2009, 53 (7): 909-924.PubMedCentralCrossRefPubMed
67.
Zhuo WL, Wang Y, Zhuo XL, Zhang YS, Chen ZT: Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to cisplatin via MAPK/mitochondrial pathway. Biochem Biophys Res Commun. 2008, 369 (4): 1098-1102.CrossRefPubMed
68.
Ansieau S, Morel AP, Hinkal G, Bastid J, Puisieux A: TWISTing an embryonic transcription factor into an oncoprotein. Oncogene. 2010, 29 (22): 3173-3184.CrossRefPubMed
69.
Pallier K, Cessot A, Cote JF, Just PA, Cazes A, Fabre E, Danel C, Riquet M, Devouassoux-Shisheboran M, Ansieau S: TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma. PLoS One. 2012, 7 (1): e29954-PubMedCentralCrossRefPubMed
70.
Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004, 117 (7): 927-939.CrossRefPubMed
71.
Ryu HS, Park Do J, Kim HH, Kim WH, Lee HS: Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer. Hum Pathol. 2012, 4 (4): 520-528.CrossRef
72.
Cool J, DeFalco TJ, Capel B: Vascular-mesenchymal cross-talk through Vegf and Pdgf drives organ patterning. Proc Natl Acad Sci U S A. 2011, 108 (1): 167-172.PubMedCentralCrossRefPubMed
73.
Yokoyama Y, Mori S, Hamada Y, Hieda M, Kawaguchi N, Shaker M, Tao Y, Yoshidome K, Tsujimoto M, Matsuura N: Platelet-derived growth factor regulates breast cancer progression via beta-catenin expression. Pathobiology: journal of immunopathology, molecular and cellular biology. 2011, 78 (5): 253-260.CrossRef
74.
Ellis PM, Al-Saleh K: Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions. Crit Rev Oncol Hematol. 2012, 84 (1): 47-58.CrossRefPubMed
75.
Gnoni A, Marech I, Silvestris N, Vacca A, Lorusso V: Dasatinib: an anti-tumour agent via Src inhibition. Curr Drug Targets. 2011, 12 (4): 563-578.CrossRefPubMed
76.
Montero JC, Seoane S, Ocana A, Pandiella A: Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res. 2011, 17 (17): 5546-5552.CrossRefPubMed
Metadata
Title
Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes
Authors
Roberto Gomez-Casal
Chitralekha Bhattacharya
Nandita Ganesh
Lisa Bailey
Per Basse
Michael Gibson
Michael Epperly
Vera Levina
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2013
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-12-94

Other articles of this Issue 1/2013

Molecular Cancer 1/2013 Go to the issue

Short communication

Late developing mammary tumors and hyperplasia induced by a low-oncogenic variant of mouse mammary tumor virus (MMTV) express genes identical to those induced by canonical MMTV

Research

Chemokine receptor CX3CR1 contributes to macrophage survival in tumor metastasis

Research

Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type

Research

Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma

Research

Role of p38 and JNK MAPK signaling pathways and tumor suppressor p53 on induction of apoptosis in response to Ad-eIF5A1 in A549 lung cancer cells

Research

Molecular changes induced by the curcumin analogue D6 in human melanoma cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits